Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 4.9 (43)
  • MEDICINE

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose

    3D AGO · VIDEO

    ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose

    In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL). Episode Highlights: ● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma ● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab ● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments ● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability Join us as we unpack these practice-changing studies and discuss their implications for community oncologists. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and highlights from oncology conferences! #ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

    14 min
  2. ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes

    JAN 7 · VIDEO

    ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes

    In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib. Key topics covered in this episode: ● The PARADIGM trial and its impact on AML treatment strategies ● Real-world evidence on shortened venetoclax dosing ● The role of menin inhibitors in combination therapies ● Patient-reported outcomes and quality of life with asciminib in CML Tune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights! #OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology

    17 min
  3. HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein

    JAN 5 · VIDEO

    HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein

    Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease. Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD). Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights! Topics Covered: • DESTINY Breast-11 and its impact on neoadjuvant therapy • Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease • HER2CLIMB-05 trial findings and implications for metastatic disease • The role of T-DXd with pertuzumab in frontline settings • The PATINA trial and its significance for triple-positive metastatic breast cancer Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

    23 min
  4. Triple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca Shatsky

    JAN 3 · VIDEO

    Triple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca Shatsky

    In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC). Join us as we discussed: * The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival. * Insights from the CITRIN study, which questions the carboplatin paradigm and highlights modern treatment approaches. * The TBCRC-056 and OlympiaN trials, investigating the combination of PARP inhibitors and immunotherapy in patients with germline BRCA and PALB2 mutations. We unpacked the implications of these studies for clinical practice, including the potential benefits and challenges of incorporating carboplatin and novel therapies into treatment regimens. Tune in for an informative discussion that aims to keep you updated on the evolving landscape of breast cancer treatment! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights from the world of oncology! #SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25

    25 min
  5. Enfortumab vedotin + Pembro FDA Approval in Muscle Invasive Bladder Cancer (MIBC): Dr. Thomas Powles

    12/31/2025 · VIDEO

    Enfortumab vedotin + Pembro FDA Approval in Muscle Invasive Bladder Cancer (MIBC): Dr. Thomas Powles

    Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included: • Overview of the Keynote-905/EV-303 study and its significance • Comparison with previous studies like the NIAGARA trial • Discussion on the side effects of EV Pembro and management strategies • The role of ctDNA in guiding post-operative therapy • Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology! #BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

    20 min
  6. Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope Rugo

    12/26/2025 · VIDEO

    Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope Rugo

    Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer. Join us as we discussed: • The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies • Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials • A critical look at the ASCENT-07 study, exploring the role of antibody-drug conjugates (ADCs) in endocrine-resistant disease We were thrilled to have Dr. Hope Rugo, a world-renowned breast medical oncologist from City of Hope, share her expertise and insights on these pivotal studies. Tune in for an informative discussion that unpacks the latest advancements in treatment options for metastatic hormone receptor-positive breast cancer, and learn how these findings may impact clinical practice. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers

    24 min
  7. Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE

    12/22/2025 · VIDEO

    Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE

    In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer. Join us as we dive into three key abstracts: 1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies. 2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy. 3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status). We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward. Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights. #SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC

    16 min
  8. Advancements and Challenges in Metastatic Colorectal Cancer Treatment

    12/21/2025 · VIDEO

    Advancements and Challenges in Metastatic Colorectal Cancer Treatment

    In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi. Key topics included: * The importance of next-generation sequencing (NGS) and biomarker testing in treatment planning. * An overview of second-line treatment options such as Tas-102 with Bevacizumab, Regorafenib, and Fruquintinib, along with their respective clinical trial data. * Insights into side effect management and quality of life considerations for patients undergoing palliative treatment. * A discussion on the recent STELLAR-303 study and its implications for immunotherapy in colorectal cancer. Join us as we bridge the gap between academia and community practice, emphasizing the need for improved treatment options and patient care in the realm of refractory colorectal cancer. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more practice-changing updates! #ColorectalCancer #mCRC #TAS102 #Regorafenib #PalliativeCare #OncologyBrothers #GIOcology

    10 min
See All (100)

4.9
out of 5
43 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like